
Dr. Shai Berlin
The Berlin Laboratory at the Technion — Israel Institute of Technology
Dr. Shai Berlin leads the Berlin Lab at the Technion — Israel Institute of Technology and specializes in the physiology and pathophysiology of NMDARs (N-methyl-D-aspartate receptors). With a Ph.D. in physiology and pharmacology from Tel Aviv University’s Faculty of Medicine and a postdoctoral fellowship at the University of California at Berkeley in Neurosciences, Dr. Berlin has extensive expertise studying NMDARs and developing innovative tools for investigating synaptic plasticity.
Since joining the Technion’s Neuroscience Department in 2016, Dr. Berlin has focused on understanding the implications of NMDARs in various diseases. His lab’s research involves advanced techniques such as electrophysiology, 2-photon and digital holography imaging, and high-throughput screening methods.
Dr. Berlin and his team investigate genetic mutations in NMDARs using diverse models, including Xenopus oocytes, cultured neurons, brain slices, and animal models.
Notably, Dr. Berlin’s group has made groundbreaking progress in identifying two exceptional GRIN2B mutations that result in an exceptional 1000-2000-fold reduction in glutamate affinity of the receptors. This discovery represents the most severe reduction in affinity ever reported for GRIN2B variants. Dr. Berlin’s cutting-edge research techniques and expertise contribute to our expanding understanding of NMDARs and their role in disease, laying the groundwork for potential therapeutic interventions.







